Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Surein Arulananda

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Translational Lung Cancer Research|November 19, 2020
Adjuvant TKI therapy in resected <i>EGFR</i>-mutant non-small-cell lung cancer-ready for prime time?Surein Arulananda, Thomas John
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 31, 2018
BRAF Mutations-A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC?Surein Arulananda, Paul Mitchell
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2019
Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?Surein Arulananda, Thomas John
Translational Lung Cancer Research|February 2, 2019
Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the boldSurein Arulananda, Paul Mitchell
Translational Lung Cancer Research|September 15, 2025
The OPEN trial-from the darkness, comes lightRichard Pham, Surein Arulananda
JAMA Oncology|September 2, 2016
The ADAM Trial: Visiting the Road Less TraveledSurein Arulananda, Thomas John
JTO Clinical and Research Reports|February 24, 2026
Immune Doublet Checkpoint Inhibition in <i>EGFR</i>-Mutated NSCLC: A Fire That Fails to Illuminate the OrchardRichard Pham, Surein Arulananda
JTO Clinical and Research Reports|March 30, 2023
Uncommon <i>EGFR</i>-Mutant NSCLC-One Drug Does Not Fit AllYang Wang, Surein Arulananda
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it?Surein Arulananda, Paul Mitchell, Thomas John
Lung Cancer Management|January 16, 2019
Combination approaches in NSCLC involving immune checkpoint inhibitorsSurein Arulananda, Gareth Rivalland, Thomas John
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Translational Lung Cancer Research|November 19, 2020
Adjuvant TKI therapy in resected <i>EGFR</i>-mutant non-small-cell lung cancer-ready for prime time?Surein Arulananda, Thomas John
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 31, 2018
BRAF Mutations-A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC?Surein Arulananda, Paul Mitchell
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2019
Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?Surein Arulananda, Thomas John
Translational Lung Cancer Research|February 2, 2019
Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the boldSurein Arulananda, Paul Mitchell
Translational Lung Cancer Research|September 15, 2025
The OPEN trial-from the darkness, comes lightRichard Pham, Surein Arulananda
JAMA Oncology|September 2, 2016
The ADAM Trial: Visiting the Road Less TraveledSurein Arulananda, Thomas John
JTO Clinical and Research Reports|February 24, 2026
Immune Doublet Checkpoint Inhibition in <i>EGFR</i>-Mutated NSCLC: A Fire That Fails to Illuminate the OrchardRichard Pham, Surein Arulananda
JTO Clinical and Research Reports|March 30, 2023
Uncommon <i>EGFR</i>-Mutant NSCLC-One Drug Does Not Fit AllYang Wang, Surein Arulananda
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it?Surein Arulananda, Paul Mitchell, Thomas John
Lung Cancer Management|January 16, 2019
Combination approaches in NSCLC involving immune checkpoint inhibitorsSurein Arulananda, Gareth Rivalland, Thomas John
Pageof 5